Does This Move Make Merck Stock a Buy?
(NYSE: MRK), a leading pharmaceutical company, generates consistent revenue and profits. However, the stock has been under pressure over the past year due to its reliance on Keytruda, its famous cancer medicine. It might be the best-selling drug in the world, but Keytruda will experience a patent cliff by the end of the decade -- a significant risk investors have to take into consideration.
Merck has been looking for ways to mitigate the risk of competition, and the drugmaker just made a move that could help along those lines. Should investors consider buying the stock?
Image source: Getty Images.
Source Fool.com
Merck KGaA Stock
€106.80
-0.650%
Our community is currently high on Merck KGaA with 4 Buy predictions and 0 Sell predictions.
As a result the target price of 135 € shows a positive potential of 26.4% compared to the current price of 106.8 € for Merck KGaA.
